Pd12-04 Sglt2 Inhibitors Associate With Overactive Bladder Symptoms

You have accessJournal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology (PD12)1 May 2024PD12-04 SGLT2 INHIBITORS ASSOCIATE WITH OVERACTIVE BLADDER SYMPTOMS J. Patrick Mershon, Taylor Weatherly, Erin Gill, Hafsa Asif, Dairon Denis-Diaz, Courtenay Moore, and Iryna Crescenze J. Patrick MershonJ. Patrick Mershon , Taylor WeatherlyTaylor Weatherly , Erin GillErin Gill , Hafsa AsifHafsa Asif , Dairon Denis-DiazDairon Denis-Diaz , Courtenay MooreCourtenay Moore , and Iryna CrescenzeIryna Crescenze View All Author Informationhttps://doi.org/10.1097/01.JU.0001008772.30001.48.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Sodium glucose co-transporter 2 inhibitors (SGLT2i) are the newest class of drugs for the treatment of diabetes mellitus type II and off-label use for heart failure and other diagnoses has been expanding. SGLT2i use results in glucosuria which has a diuretic effect. Diuresis and glucosuria together may provoke or exacerbate overactive bladder (OAB) symptoms such as urinary frequency, urgency, and urgency incontinence. Additionally, higher rates of infection may be seen with glucosuria. In this study we aim to correlate OAB symptoms and infections in a group of patients before and after starting SGLT2i. METHODS: Patients>18 years of age starting SGLT2i in outpatient clinics were prospectively enrolled between January 1 and November 1, 2023. Indications for the prescription were either heart failure or diabetes mellitus type II. Patients were asked to complete OAB-q short form and screening questions on urinary tract infection history. Patients were then approached six weeks after starting the medication to repeat the same questionnaire. Retrospective chart review was combined with the patient reported outcomes to establish demographics, baseline clinical characteristics, and UTI rates including microbiology data. Paired t-tests were used to compare survey responses (total score and each question score) before and after starting the medication. RESULTS: Twenty-three patients completed both surveys with an average age of 59.5 (+/- 14.3 STDEV) and BMI 35.0 +/- 8.9. Average hemoglobin A1c was 6.88 +/- 1.6 and median Charlson Comorbidity Index was 4. Average total score on the OAB-q survey was 32.9 before initiation and 36.3 after six weeks of medication use. Total score approached but did not meet significance for worsening of symptoms after starting SGLT2i (p=0.065). Loss of small amounts of urine and frustration with time spent in the restroom worsened (p=0.019 and 0.027, respectively). UTI rates and yeast infections did not differ before and after starting the medication (p>0.05). CONCLUSIONS: SGLT2i use is associated with increased OAB symptoms on certain questions on the OAB-q short form bother score. Prescribers should counsel patients on the possible bladder side effects of the medication and be prepared to offer alternative therapies. Other providers including urologists need to be aware of SGLT2i contribution to OAB symptoms within this population and discuss multi-disciplinary management with other care providers. Much work remains to be done to further quantify the effects of this new class of medication, including continued evaluation of infection rates and symptom changes with longer-term use. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e257 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information J. Patrick Mershon More articles by this author Taylor Weatherly More articles by this author Erin Gill More articles by this author Hafsa Asif More articles by this author Dairon Denis-Diaz More articles by this author Courtenay Moore More articles by this author Iryna Crescenze More articles by this author Expand All Advertisement PDF downloadLoading ...